Early treatment correlates with better immune fitness, marked by higher CD4-positive naive T cells and a favorable tumor microenvironment. Cilta-cel therapy shows improved outcomes in earlier ...

The 2-year event-free survival (EFS) rate in the treatment arm was 76.3% (95% CI, 61.1%-86.1%), and the 2-year overall survival (OS) rate was 82.0% (95% CI, 67.1%-90.6%). These results showed that the ...

Outcomes at one year demonstrated that high-degree mismatching did not adversely affect patient survival when PTCy was ...

Critically, metastatic recurrence has significant prognostic implications. In this cohort, patients who experienced ...

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...

Initial data from a phase 2 (NCT05256290) clinical trial show that silevertinib yields robust antitumor activity and ...

Oncology and primary care often operate in silos, leading to communication gaps and unclear roles in patient care management.

Sabari, MD, assistant professor at NYU Grossman School of Medicine in New York, discussed the phase 3 IMforte trial ...

With the 2025 American Society of Hematology (ASH) Meeting & Exposition kicking off on Saturday, December 6, in Orlando, Florida, Targeted Oncology is bringing you background on the most exciting ...

Despite significant advancements in medical technology and procedural safety, the speaker emphasizes that relapse remains the ...

Lisocabtagene maraleucel is the first CAR T-cell therapy approved for relapsed or refractory MZL, expanding treatment options ...

Naxitamab plus GM-CSF demonstrated strong antitumor activity and manageable toxicity in high-risk neuroblastoma patients, ...